Global Coronavirus Partnering 2014 to 2021 provides the full collection of Coronavirus disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Trends in Coronavirus partnering deals Financial deal terms for headline, upfront and royalty by stage of development Coronavirus partnering agreement structure Coronavirus partnering contract documents Top Coronavirus deals by value Most active Coronavirus dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Coronavirus disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Coronavirus deals.
The report presents financial deal terms values for Coronavirus deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Coronavirus dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Coronavirus dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Coronavirus deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Coronavirus dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Coronavirus deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Coronavirus partnering deals by specific Coronavirus target announced since 2014. The chapter is organized by specific Coronavirus therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Coronavirus partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Coronavirus partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Coronavirus technologies and products.
Report scope Global Coronavirus Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Coronavirus trends and structure of deals entered into by leading companies worldwide.
Global Coronavirus Partnering 2014 to 2021 includes: Trends in Coronavirus dealmaking in the biopharma industry since 2014 Access to headline, upfront, milestone and royalty data Access to hundreds of Coronavirus deal contract documents Comprehensive access to over 1000 Coronavirus deal records The leading Coronavirus deals by value since 2014 Most active Coronavirus dealmakers since 2014
In Global Coronavirus Partnering 2014 to 2021, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Coronavirus Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 1000 Coronavirus deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Medical Thawing System Market by Sample Type (Blood, Embryo, Ovum, and Semen) and End User (Blood Banks, Hospitals, Tissue Banks, Pharmaceutical & Biotech Companies, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027 The global medical thawing system market was valued at $165.82 million in 2019...
703 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2021
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to the analysis,...
555 pages •
By Global Industry Analysts
• Apr 2021
- Most R&D budgets which are so vital for innovation are largely dependent upon financial support from governments. Healthy financial performance of companies also determines the extent of willingness to reinvest earnings into R&D and new product development. The COVID-19 induced recession has now cast serious...
The North America yeast extract market is expected to reach US$ 561.2 million in 2027 from US$ 389.6 million in 2019. The market is estimated to grow at a CAGR of 4.7% during 2020–2027. The growth the North America yeast extract market is attributed to the key driving factors such as the rising demand for natural ingredients in the...
The chromatography resin market size is estimated to be USD 2.2 billion in 2020 and is projected to reach USD 3.3 billion by 2025, at a CAGR of 8.2% between 2020 and 2025. Factors such as increasing demand for therapeutic antibodies, public-private investment in pharmaceutical & life science research, and rising concern for food safety will...
2021 Top 10 Biotechnology Companies SWOT Analsis--Capabilities, Goals and Strategies
In the dynamic and fragmented Biotechnology industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The Global Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides details of the latest distribution agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of distribution agreements from...
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2021 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The report provides a detailed understanding and analysis of how and why companies enter business, product,...
131 pages •
By Global Industry Analysts
• Apr 2021
- Global Lysosomal Storage Diseases Market to Reach $10.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Lysosomal Storage Diseases estimated at US$7 Billion in the year 2020, is projected to reach a revised size of US$10.3 Billion by 2027, growing at a CAGR of 5.6% over the analysis period...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.